Medication info
VR Tablets 20/80 mg

VR Tablets 20/80 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletValsartan›80mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
Brown round film-coated tablets
Packaging
30 tablets/box[(10 tablets/PTP)*3]
Approval status
Active

MFDS item code 202003038 · Approved 2020.04.24

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; inhibition of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This drug should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the drug be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily, or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose doses cannot be reduced), initiate treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this drug once daily; the dose should not exceed 80 mg once daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this drug orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this drug twice daily. Over the following weeks, the dose may be increased, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Dose reduction should be considered if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, since there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this drug. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this drug is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; inhibition of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
  • hyperlipidemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
View approved original text

This medication is used only in patients who need to take both valsartan and rosuvastatin together. Valsartan is used in patients with essential hypertension and heart failure, especially in cases where there is intolerance to ACE inhibitors, and it reduces the risk of death in patients with left ventricular dysfunction after myocardial infarction. Rosuvastatin is used as an adjunctive treatment in patients with hyperlipidemia and dyslipidemia who are not controlled by diet and exercise, lowering total cholesterol and LDL cholesterol, thereby delaying the progression of atherosclerosis. In addition, it helps reduce the risk of cardiovascular diseases, including stroke, myocardial infarction, and need for vascular revascularization. This medication works effectively on both conditions to improve the patient's cardiovascular health.

How to take

Adult dose

This drug should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the drug be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily, or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose doses cannot be reduced), initiate treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this drug once daily; the dose should not exceed 80 mg once daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this drug orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this drug twice daily. Over the following weeks, the dose may be increased, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Dose reduction should be considered if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, since there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this drug. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this drug is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it must be stopped immediately if pregnancy is confirmed. Women of childbearing potential should use suitable contraceptive methods, and breastfeeding women should preferably avoid taking this medication. Patients with an allergic reaction to this medication or severe impairment of liver or kidney function should not take it. Caution is also needed in patients with a history of muscle disorders or those taking certain medications concurrently. Elderly patients, patients with hyperkalemia, liver dysfunction, etc., should take it cautiously under medical supervision. If symptoms such as muscle pain, weakness, or cramps occur during treatment, consult a doctor immediately, and regular testing of liver and kidney function is advisable. As blood pressure may drop rapidly, dizziness or fainting may occur; therefore, caution is needed when driving or operating machinery. Since this medication can interact with other drugs, it is essential to inform healthcare providers of any other medications being taken. There is no specific antidote for overdose; therefore, immediate hospitalization and appropriate treatment should be sought. It should be kept out of reach of children, and it is safe not to transfer to another container during storage.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver aminotransferase levels, increased serum creatinine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory disturbance, anxiety, upper respiratory tract infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetic complications, leg fracture, spinal fracture, fracture, skin mass, second-degree AV block, vestibular neuritis, retinal detachment, unspecified skin tumor-like condition, herpes zoster, intervertebral disc herniation, hemoptysis, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, hypertension exacerbation, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, localized skin reaction, palpitations, angina exacerbation, auditory disturbances, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, headache, dizziness, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, throat inflammation, arthralgia, hypotension, orthostatic dizziness, orthostatic hypotension, renal impairment, hyperkalemia, drowsiness, atrial fibrillation, loss of appetite, malaise, vascular edema, erythema, itching, serum sickness, vasculitis, hepatitis, arrhythmia, intestinal vascular edema, interstitial pneumonia, hypoglycemia, shock, syncope, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased hematocrit, decreased hemoglobin, edema, insomnia, rash, decreased libido, vertigo, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, weakness, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, jaundice, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, and ocular muscle weakness.

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a special container that does not allow light to enter and at a temperature between 1 and 30 degrees Celsius. This ensures the maintenance of the drug's effectiveness and safety.

Appearance and packaging

Appearance

Brown round film-coated tablets

Package unit

30 tablets/box[(10 tablets/PTP)*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.